Christine Allen

Christine Allen is a Canadian Professor and the first-ever Associate Vice-President and Vice-Provost, Strategic Initiatives at the University of Toronto.[1] She served formerly as Interim Dean of the university's Leslie Dan Faculty of Pharmacy. She is co-founder of Nanovista, a company focused on imaging of tumors.[2] Currently, she serves as Associate Editor of Molecular Pharmaceutics.[3] She received her PhD in Chemistry at McGill University and completed a post doc in the Department of Advanced Therapeutics at the BC Cancer Agency. Prior to joining the University of Toronto in 2002 she worked as a scientist and assistant directors of materials research at Celator Pharmaceuticals.[3] Dr. Allen's research is focused on the field of drug delivery, in particular, micelles and gold nanoparticles for cancer therapy.[4][5] She has developed several block-co-polymers, particularly those with PEG, for delivery of cancer chemotherapeutics.[4] For cancer imaging as well as theranostic applications, the Allen lab has developed several gold nanoparticle carriers.[5] Her platforms apply concepts in drug delivery, targeted drug delivery, as well as controlled release. She has numerous patents, and over 90 publications.[3] Also, she has received many awards including:

  • Fellow of the Canadian Academy of Health Sciences[6]
  • 2014 Gattefossé Canada/CSPS Award in Lipid-Based Drug Delivery[7]
  • 2011 CRS/Elsevier Journal of Controlled Release Jorge Heller Award for Outstanding Paper[8]
  • Innovation Award - Ontario Research and Commercialization Program, 2008
  • Career Award - Canadian Institutes of Health Research (CIHR)/Rx&D, 2004-2009
  • New Investigator Research Award - Association of Faculties of Pharmacy of Canada (AFPC)/AstraZeneca, 2006
  • Early Career Award - Canadian Society for Pharmaceuticals Sciences (CSPS)/GlaxoSmithKline, 2006

References
  1. Kalvapalle, Rahul (July 5, 2019). "Christine Allen appointed U of T's first associate vice-president and vice-provost, strategic initiatives". U of T News. Retrieved September 1, 2019.
  2. "Christine Allen Women enabling science to reach the people who need it". Johnson & Johnson Innovation Labs. Archived from the original on 1 November 2018. Retrieved 30 July 2018.
  3. "Christine Allen". Controlled Release Society. Retrieved 30 July 2018.
  4. Houdaihed, L; Evans, JC; Allen, C (2017). "Overcoming the Road Blocks: Advancement of Block Copolymer Micelles for Cancer Therapy in the Clinic". Mol. Pharm. 14 (8): 2503–2517. doi:10.1021/acs.molpharmaceut.7b00188. PMID 28481116.
  5. Her, S; Jaffray, DA; Allen, C (2017). "Gold nanoparticles for applications in cancer radiotherapy: Mechanisms and recent advancements". Adv Drug Deliv Rev. 109: 84–101. doi:10.1016/j.addr.2015.12.012. PMID 26712711.
  6. Kalvapalle, Rahul (September 20, 2019). "10 U of T researchers named fellows of the Canadian Academy of Health Sciences". U of T News. Retrieved October 4, 2019.
  7. Dou, Yannan; Zheng, Jinzi; Foltz, Warren; Weersink, Robert; Chaudary, Naz; Jaffray, David; Allen, Christine (25 September 2011). "Heat-activated thermosensitive liposomal cisplatin (HTLC) results in effective growth delay of cervical carcinoma in mice". Journal of Controlled Release. 178 (23): 69–78. doi:10.1016/j.jconrel.2014.01.009. PMID 24440663.
  8. Dunn, Michael; Zheng, Jinzi; Rosenblat, Joshua; Jaffray, David; Allen, Christine (25 September 2011). "APN/CD13-targeting as a strategy to alter the tumor accumulation of liposomes". Journal of Controlled Release. 154 (3): 298–305. doi:10.1016/j.jconrel.2011.05.022. PMID 21640146.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.